Phase 2, Multicenter, Open-Label, Two-Stage Study to Evaluate the Safety and Efficacy of Intra-Arterial Catheter-Directed Alfimeprase for Restoration of Neurologic Function and Rapid Opening of Arteries in Stroke (CARNEROS-1).

Trial Profile

Phase 2, Multicenter, Open-Label, Two-Stage Study to Evaluate the Safety and Efficacy of Intra-Arterial Catheter-Directed Alfimeprase for Restoration of Neurologic Function and Rapid Opening of Arteries in Stroke (CARNEROS-1).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs Alfimeprase (Primary)
  • Indications Embolism and thrombosis; Stroke
  • Focus Therapeutic Use
  • Acronyms CARNEROS-1
  • Sponsors Nuvelo
  • Most Recent Events

    • 05 May 2009 Sponsor, affiliate and lead trial centre (ARCA Biopharma) added as reported by ClinicalTrials.gov.
    • 17 Mar 2008 Status changed from recruiting to discontinued: Nuvelo have decided to terminate their clinical development of alfimeprase after obtaining disappointing efficacy results in the SONOMA-3 trial [see media release 9086453 and profile 700018108].
    • 12 Dec 2007 First patient dosed according to Nuvelo media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top